MMRF PRESS RELEASES
Multiple Myeloma Research Foundation (MMRF) Awarded with Highest Rating from Charity Navigator for Exceptional Fiscal Management
MMRF Ranked in Top One Percent of Nonprofits for Outstanding Stewardship of Donors? Funds
Norwalk, Conn. — January 4, 2011
The Multiple Myeloma Research Foundation (MMRF) announced today that Charity Navigator, America's premier independent evaluator of charitable organizations, has awarded the MMRF with 4-star rating, the highest rating possible, for the eighth consecutive year demonstrating exceptional fiscal responsibility in its efforts to bring patients the next generation of treatments and find a cure for multiple myeloma.
This distinguished recognition is an honor that only one percent of charities nationwide have earned. According to Charity Navigator, “this exceptional designation differentiates the MMRF from its peers and demonstrates to the public it is worthy of their trust.”
"Charity Navigator’s 4-star rating underscores our tireless commitment to accountability and measurable results” said Kathy Giusti, Founder and CEO of the MMRF. “In this economy, we know that it is more important than ever to keep a watchful eye on all of our expenses and to make the most of the hard-earned dollars that are donated to the MMRF. Our supporters can be certain that we maximize every dollar they invest with us to develop innovative myeloma treatments which are extending patient lives as we make progress toward finding a cure.”
In addition to receiving the 4-star rating from Charity Navigator, the MMRF has received a "Best in America" Seal of Excellence from the Independent Charities of America, an A rating from the American Institute of Philanthropy, and is in compliance with all of the Better Business Bureau's (BBB) Wise Giving Alliance Standards for Charity Accountability. The MMRF has also received approval from the National Cancer Institute for its research grants program.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $150 million since its inception to fund nearly 120 laboratories worldwide, including 60 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org
Media Contact: Terri Clevenger, 203-227-0209, email@example.com